Clinical trials: Glycemic Control, open to volunteers
Postprandial Glycemic Control, Prediabetic Overweight and Obese Adults
A Two-part Study of Lembas Edge Evaluating Tolerability and Postprandial Glycemic Control
The goal of part 1 of this clinical trial is to investigate the tolerability of Lembas Edge in healthy adults. The objective of Part 2 of this study is to investigate the efficacy of Lembas Edge on postprandial glycemic control…
- Trial name
- NCT07711288
- Testing
- Low dose alpha-galactosidase-derived peptide, Medium dose alpha-galactosidase-derived peptide, High dose alpha-galactosidase-derived peptide
- Where
- Canada
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Lembas
Diabetes Type 2, Diabetes
Study Evaluating the Metabolic Effects of pulsENDO Therapy in Adults With Type 2 Diabetes
This is a prospective, multicenter, randomized, double-blind, sham-controlled, adaptive study evaluating the pulsENDO system in individuals with type 2 diabetes (T2D) inadequately controlled on non-insulin glucose-lowering…
- Conditions
- Diabetes Type 2, Diabetes, Diabetes (DM), Weight Change
- Trial name
- pulsENDO (NCT07768631)
- Testing
- pulsENDO Therapy
- Volunteers
- 320 people
- Sponsor
- Endogenex, Inc.
Normoglycemia, Prediabetes
Effect of Chronic Exposure to Nextida GC-B on Glycemic Control in Adults With Normoglycemia or Prediabetes
The goal of this clinical trial is to investigate the safety and efficacy of Nextida GC-B on glycemic control in adults with normoglycemia and prediabetes.
- Conditions
- Normoglycemia, Prediabetes, Glycemic Control
- Trial name
- NCT07149064
- Testing
- Nextida GC-B
- Where
- Canada
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Rousselot BVBA
Liver Fat, Liver Fibrosis
Effect of Erugliflozin On Liver Fat, Liver Fibrosis and Glycemic Control in Type II DM Patients With NASH/NAFLD
Open-label, prospective, single-arm, multicenter study to determine effects of Ertugliflozin on liver fat, liver fibrosis \& glycemic control in subjects with Type 2 Diabetes Mellitus (T2DM) with Non-Alcoholic Fatty Liver Disease…
- Conditions
- Liver Fat, Liver Fibrosis, Glycemic Control, Body Weight Changes
- Trial name
- Ertu-NASH (NCT05644717)
- Testing
- Ertugliflozin 5 mg, 15mg
- Where
- Pakistan
- Volunteers
- 164 people
- Sponsor
- Getz Pharma